Nuvalent to Host Conference Call to **Discuss Preliminary** Phase 1 Data from **ARROS-1** Clinical Trial of NVL-520 and **Additional Preclinical Updates in Conjunction** with 34th EORTC-NCI-**AACR** Symposium

CAMBRIDGE, Mass., Oct. 17, 2022 /<u>PRNewswire</u>/ -- <u>Nuvalent, Inc.</u> (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating *precisely* targeted therapies for clinically proven kinase targets in cancer, today announced that management will host a live webcast and conference call in conjunction with its <u>data presentations at the 34th EORTC-NCI-AACR (ENA) Symposium</u> in Barcelona, Spain on Friday, October 28, 2022 at 8:30 a.m. EDT.

The event will be accessible through the "Events" section of the Investors page of <u>www.nuvalent.com</u> or by dialing (866) 652-5200 (domestic) or (412) 317-6060 (international) and referring to conference ID 10171503. A replay and accompanying slides will be archived on the Nuvalent website for 30 days.

About Nuvalent

Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating *precisely* targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive non-small cell lung cancer (NSCLC), a program in HER2 Exon 20 insertion-positive cancers, along with multiple discovery-stage research programs. We routinely post information that may be important to investors on our website at <u>www.nuvalent.com</u>. Follow us on Twitter (<u>@nuvalent</u>) and <u>LinkedIn</u>.

SOURCE Nuvalent, Inc.

Investor Contact Chelcie Lister THRUST Strategic Communications <u>chelcie@thrustsc.com</u>

Media Contact Amanda Sellers Verge Scientific Communications asellers@vergescientific.com

https://investors.nuvalent.com/2022-10-17-Nuvalent-to-Host-Conference-Call-to-Discuss-Preliminary-Phase-1-Data-from-ARROS-1-Clinical-Trial-of-NVL-520-and-Additional-Preclinical-Updates-in-Conjunction-with-34th-EORTC-NCI-AACR-Symposium